Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of “Moderate Buy” by Analysts
by Doug Wharley · The Cerbat GemAardvark Therapeutics, Inc. (NASDAQ:AARD – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $22.60.
A number of analysts recently issued reports on AARD shares. Morgan Stanley reissued an “equal weight” rating and set a $7.00 price objective (down from $29.00) on shares of Aardvark Therapeutics in a research report on Monday, March 2nd. William Blair began coverage on shares of Aardvark Therapeutics in a research report on Friday, December 12th. They issued an “outperform” rating on the stock. Oppenheimer lowered their target price on shares of Aardvark Therapeutics from $35.00 to $21.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research report on Friday, March 27th. Finally, HC Wainwright reissued a “neutral” rating on shares of Aardvark Therapeutics in a research note on Monday, March 2nd.
Check Out Our Latest Analysis on AARD
Institutional Trading of Aardvark Therapeutics
Institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Aardvark Therapeutics during the second quarter worth $42,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Aardvark Therapeutics during the fourth quarter worth $47,000. Persistent Asset Partners Ltd acquired a new stake in shares of Aardvark Therapeutics in the fourth quarter valued at $56,000. New York State Common Retirement Fund acquired a new stake in shares of Aardvark Therapeutics in the second quarter valued at $99,000. Finally, MetLife Investment Management LLC purchased a new stake in shares of Aardvark Therapeutics in the 4th quarter valued at $102,000.
Aardvark Therapeutics Stock Performance
Shares of Aardvark Therapeutics stock opened at $4.30 on Wednesday. The stock has a 50 day moving average of $8.75 and a 200 day moving average of $11.40. The firm has a market capitalization of $93.83 million, a price-to-earnings ratio of -1.47 and a beta of 5.33. Aardvark Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $17.94.
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last posted its earnings results on Monday, March 23rd. The company reported ($0.81) EPS for the quarter, meeting analysts’ consensus estimates of ($0.81).
About Aardvark Therapeutics
Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.
The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.